Advances in Targeted and Systemic Therapy for Salivary Gland Carcinomas: Current Options and Future Directions
Salivary gland carcinomas (SGCs) represent a rare and heterogeneous group of malignancies accounting for 3–6% of all head and neck cancers. While surgical resection and radiotherapy remain the standard for locoregional control, systemic treatment is indicated for recurrent or metastatic disease. Adv...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-04-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/32/4/232 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850144954509164544 |
|---|---|
| author | Sushanth Sreenivasan Rahim A. Jiwani Richard White Veli Bakalov Ryan Moll Joseph Liput Larisa Greenberg |
| author_facet | Sushanth Sreenivasan Rahim A. Jiwani Richard White Veli Bakalov Ryan Moll Joseph Liput Larisa Greenberg |
| author_sort | Sushanth Sreenivasan |
| collection | DOAJ |
| description | Salivary gland carcinomas (SGCs) represent a rare and heterogeneous group of malignancies accounting for 3–6% of all head and neck cancers. While surgical resection and radiotherapy remain the standard for locoregional control, systemic treatment is indicated for recurrent or metastatic disease. Advances in molecular profiling have identified actionable targets such as NTRK gene fusions, HER2, immune checkpoint regulators, androgen receptors, and RET receptors. These have facilitated the development of targeted therapies, including TRK inhibitors, HER2-directed agents, and androgen receptor modulators, as well as emerging combinations of immunotherapy and chemotherapy. Despite these advancements, challenges such as resistance mechanisms and limited therapeutic efficacy persist. Overall response rates remain relatively low across most systemic therapies, reflecting a persistent unmet clinical need. This review discusses the current landscape of treatment options and explores promising clinical trials and future directions to enhance outcomes for patients with SGCs. |
| format | Article |
| id | doaj-art-57ffd16f9c4f4b05b3aecfd987e01c15 |
| institution | OA Journals |
| issn | 1198-0052 1718-7729 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj-art-57ffd16f9c4f4b05b3aecfd987e01c152025-08-20T02:28:12ZengMDPI AGCurrent Oncology1198-00521718-77292025-04-0132423210.3390/curroncol32040232Advances in Targeted and Systemic Therapy for Salivary Gland Carcinomas: Current Options and Future DirectionsSushanth Sreenivasan0Rahim A. Jiwani1Richard White2Veli Bakalov3Ryan Moll4Joseph Liput5Larisa Greenberg6Division of Internal Medicine, Allegheny Health Network, 320 East North Ave, Pittsburgh, PA 15212, USADivision of Medical Oncology, Allegheny Health Network, 314 East North Ave, Pittsburgh, PA 15212, USADivision of Medical Oncology, Allegheny Health Network, 314 East North Ave, Pittsburgh, PA 15212, USADivision of Medical Oncology, Allegheny Health Network, 314 East North Ave, Pittsburgh, PA 15212, USADivision of Medical Oncology, Allegheny Health Network, 314 East North Ave, Pittsburgh, PA 15212, USADivision of Medical Oncology, Allegheny Health Network, 314 East North Ave, Pittsburgh, PA 15212, USADivision of Medical Oncology, Allegheny Health Network, 314 East North Ave, Pittsburgh, PA 15212, USASalivary gland carcinomas (SGCs) represent a rare and heterogeneous group of malignancies accounting for 3–6% of all head and neck cancers. While surgical resection and radiotherapy remain the standard for locoregional control, systemic treatment is indicated for recurrent or metastatic disease. Advances in molecular profiling have identified actionable targets such as NTRK gene fusions, HER2, immune checkpoint regulators, androgen receptors, and RET receptors. These have facilitated the development of targeted therapies, including TRK inhibitors, HER2-directed agents, and androgen receptor modulators, as well as emerging combinations of immunotherapy and chemotherapy. Despite these advancements, challenges such as resistance mechanisms and limited therapeutic efficacy persist. Overall response rates remain relatively low across most systemic therapies, reflecting a persistent unmet clinical need. This review discusses the current landscape of treatment options and explores promising clinical trials and future directions to enhance outcomes for patients with SGCs.https://www.mdpi.com/1718-7729/32/4/232salivary gland carcinomatargeted therapyhead and neck tumorsimmunotherapypleomorphic adenomachemotherapy |
| spellingShingle | Sushanth Sreenivasan Rahim A. Jiwani Richard White Veli Bakalov Ryan Moll Joseph Liput Larisa Greenberg Advances in Targeted and Systemic Therapy for Salivary Gland Carcinomas: Current Options and Future Directions Current Oncology salivary gland carcinoma targeted therapy head and neck tumors immunotherapy pleomorphic adenoma chemotherapy |
| title | Advances in Targeted and Systemic Therapy for Salivary Gland Carcinomas: Current Options and Future Directions |
| title_full | Advances in Targeted and Systemic Therapy for Salivary Gland Carcinomas: Current Options and Future Directions |
| title_fullStr | Advances in Targeted and Systemic Therapy for Salivary Gland Carcinomas: Current Options and Future Directions |
| title_full_unstemmed | Advances in Targeted and Systemic Therapy for Salivary Gland Carcinomas: Current Options and Future Directions |
| title_short | Advances in Targeted and Systemic Therapy for Salivary Gland Carcinomas: Current Options and Future Directions |
| title_sort | advances in targeted and systemic therapy for salivary gland carcinomas current options and future directions |
| topic | salivary gland carcinoma targeted therapy head and neck tumors immunotherapy pleomorphic adenoma chemotherapy |
| url | https://www.mdpi.com/1718-7729/32/4/232 |
| work_keys_str_mv | AT sushanthsreenivasan advancesintargetedandsystemictherapyforsalivaryglandcarcinomascurrentoptionsandfuturedirections AT rahimajiwani advancesintargetedandsystemictherapyforsalivaryglandcarcinomascurrentoptionsandfuturedirections AT richardwhite advancesintargetedandsystemictherapyforsalivaryglandcarcinomascurrentoptionsandfuturedirections AT velibakalov advancesintargetedandsystemictherapyforsalivaryglandcarcinomascurrentoptionsandfuturedirections AT ryanmoll advancesintargetedandsystemictherapyforsalivaryglandcarcinomascurrentoptionsandfuturedirections AT josephliput advancesintargetedandsystemictherapyforsalivaryglandcarcinomascurrentoptionsandfuturedirections AT larisagreenberg advancesintargetedandsystemictherapyforsalivaryglandcarcinomascurrentoptionsandfuturedirections |